Biofrontera AG (XTER:B8F) ROCE % : -59.62% (As of Sep. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Biofrontera AG ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Biofrontera AG's annualized ROCE % for the quarter that ended in Sep. 2023 was -59.62%.

Biofrontera AG ROCE % Historical Data

The historical data trend for Biofrontera AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biofrontera AG ROCE % Chart

Biofrontera AG Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

-74.25

-5.29

-20.27

73.81

-103.73

Biofrontera AG Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
ROCE %	Get a 7-Day Free Trial															-90.63	-47.73	-63.84	18.45	-59.62

Biofrontera AG ROCE % Calculation

Biofrontera AG's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-43.047	/	( ( (76.127 - 17.467)	+	(32.725 - 8.387) )	/ 2 )
	=	-43.047	/	( (58.66	+	24.338)	/ 2 )
	=	-43.047	/	41.499
	=	-103.73 %

Biofrontera AG's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	-9.764	/	( ( (27.571 - 9.559)	+	(24.019 - 9.277) )	/ 2 )
	=	-9.764	/	( ( 18.012	+	14.742 )	/ 2 )
	=	-9.764	/	16.377
	=	-59.62 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

Biofrontera AG (XTER:B8F) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Biofrontera AG ROCE % Related Terms

Thank you for viewing the detailed overview of Biofrontera AG's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Biofrontera AG (XTER:B8F) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biofrontera AG (XTER:B8F) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

B8F:Germany B8F:Germany B8F:Germany

Address

Hemmelrather Weg 201, Leverkusen, NW, DEU, 51377

Website

https://www.biofrontera.com

Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin.

Biofrontera AG (XTER:B8F) Headlines

No Headlines